Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA-PET/CT selection and genomic biomarkers for Radium-223 in metastatic castration-resistant prostate cancer
NL-OMON57275Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label trial of radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC) (3 cohorts), sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical progression-free survival. Started Mar 2025; status: recruiting.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON57275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON57275.